Plaque assay with spleen cells forming alloantibodies to H-2 a and H-2 d specificities.
Explore the source record for details and available documents.
Animals↗
Biomedical subjects
H Fuji
Publications and source records attributed to H Fuji.
Evidence for multigenic control of immune response to theta-AKR antigen in mice.
Explore the source record for details and available documents.
Animals↗
[Cephalometric changes in treatment of anterior crossbite cases with the chin cap].
Explore the source record for details and available documents.
Cephalometry↗
[Five severe class 3 malocclusion cases treated using orthopedic force].
Explore the source record for details and available documents.
Malocclusion↗
Genetic control of immune response to theta-AKR alloantigen.
Explore the source record for details and available documents.
Animals↗
Immunologic injury of renal homografts.
Explore the source record for details and available documents.
Animals↗
Plaque-forming-cell response to H-2 antigens of mice.
Explore the source record for details and available documents.
Animals↗
Studies of formation of transplantation antibodies in mouse parabiosis.
Explore the source record for details and available documents.
Alleles↗
Allogenic nucleated cells as immunogen and target for plaque-forming cells in mice.
Explore the source record for details and available documents.
Animals↗
Immune response to alloantigens of thymus studied in mice with plaque assay.
Explore the source record for details and available documents.
Animals↗
Cytolysis in agar of thymus cells by antibody-forming cells.
Explore the source record for details and available documents.
Agar↗
Primary immune response in vitro: reversible suppression by anti-globulin antibodies.
Explore the source record for details and available documents.
Animals↗
[Studies on pentachlorophenol].
Explore the source record for details and available documents.
Escherichia coli↗
Use of daily low-dose carboplatin in radiotherapy for non-small cell lung cancer.
The feasibility of using low-dose carboplatin (CBDCA) as a radiopotentiator in radiotherapy(RT) for non-small cell lung cancer(NSCLC) patients with unfavorable factors was studied. Fifteen patients with locally advanced and inoperable NSCLC were treated with RT in combination with daily 20 mg/m2 CBDCA. Twelve patients completed the treatment as planned. Thrombocytopenia and leukocytopenia(WHO Grade > or = 3) were observed in 1 and 2 patients, respectively. A complete and a partial response were obtained in 1(6.7%) and 9(60%) patients, respectively. The median survival time was 11 months. Calvert's formula has been used for carboplatin dosing and creatinine clearance applies in place of glomerular filtration rate in the formula. In this schedule, there was no correlation between pretreatment creatinine clearance and the nadir of platelet count(p = 0.9016). The combined use of daily low-dose CBDCA to RT was feasible for NSCLC patients with unfavorable factors.
Adenocarcinoma↗